AMAG Pharmaceuticals Inc (AMAG.OQ)
22.25USD
1:30am IST
$0.20 (+0.91%)
$22.05
$22.05
$22.35
$21.70
81,297
190,781
$25.60
$11.93
About
Overall
| Beta: | 0.91 |
| Market Cap(Mil.): | $661.66 |
| Shares Outstanding(Mil.): | 35.29 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| AMAG.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 30.93 | 32.76 |
| EPS (TTM): | -1.39 | -- | -- |
| ROI: | -2.17 | 15.07 | 14.61 |
| ROE: | -4.83 | 16.60 | 16.34 |
BRIEF-AMAG Pharmaceuticals Announces Q1 Loss Per Share $1.59
* AMAG PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND RAISES FULL YEAR FINANCIAL GUIDANCE
BRIEF-AMAG Pharmaceuticals Appoints J. Alan Butcher As Executive Vice President
* AMAG PHARMACEUTICALS APPOINTS J. ALAN BUTCHER AS EXECUTIVE VICE PRESIDENT AND CHIEF BUSINESS OFFICER Source text for Eikon: Further company coverage:
BRIEF-AMAG Pharmaceuticals Submits NDA To FDA For Bremelanotide
* AMAG PHARMACEUTICALS SUBMITS A NEW DRUG APPLICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION FOR BREMELANOTIDE FOR THE TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) IN PREMENOPAUSAL WOMEN Source text for Eikon: Further company coverage:
BRIEF-AMAG Pharmaceuticals and Sandoz Enters Stipulation Of Dismissal
* AMAG PHARMACEUTICALS - CO, SANDOZ ENTERED STIPULATION OF DISMISSAL, PURSUANT TO SETTLEMENT AGREEMENT, THAT DISMISSES, RESOLVES PATENT LITIGATION
BRIEF-AMAG Reports Q4 Earnings Of $0.10 Per Share
* TOTAL GAAP REVENUES FOR Q4 OF 2017 WERE $158.3 MILLION, COMPARED WITH $151.6 MILLION
BRIEF-AMAG Gets FDA Approval Of Makena Subcutaneous Auto-Injector
* AMAG PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF MAKENA® (HYDROXYPROGESTERONE CAPROATE INJECTION) SUBCUTANEOUS AUTO-INJECTOR TO REDUCE THE RISK OF PRETERM BIRTH IN CERTAIN AT-RISK WOMEN
BRIEF-AMAG Pharmaceuticals Announces FDA Approval Of Supplemental New Drug Application (SNDA) For Feraheme
* AMAG PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) FOR FERAHEME® (FERUMOXYTOL INJECTION) Source text for Eikon: Further company coverage:
Competitors
| Price | Chg | |
|---|---|---|
| Takeda Pharmaceutical Co Ltd (4502.T) | ¥4,725 | -5.00 |
| Sanofi SA (SASY.PA) | €72.51 | +0.67 |
| Fresenius Medical Care AG & Co. KGaA (FMEG.DE) | €85.60 | -0.32 |
| Vifor Pharma AG (VIFN.S) | -- | -- |
Estimates